Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group.

Graham BS, Keefer MC, McElrath MJ, Gorse GJ, Schwartz DH, Weinhold K, Matthews TJ, Esterlitz JR, Sinangil F, Fast PE.

Ann Intern Med. 1996 Aug 15;125(4):270-9.

PMID:
8678389
2.

Human studies in the development of human immunodeficiency virus vaccines.

Dolin R.

J Infect Dis. 1995 Nov;172(5):1175-83. Review.

PMID:
7594651
3.

Vaccines directed against HIV: preventive and therapeutic strategies.

Kahn JO, Birx DL.

AIDS Clin Rev. 1993-1994:213-38. Review.

PMID:
8217900
4.

[HIV vaccine trials].

Ikuta K.

Hokkaido Igaku Zasshi. 1993 Sep;68(5):603-8. Review. Japanese.

PMID:
8225164
5.

HIV vaccines for prevention of infection and disease in humans.

Dolin R.

Infect Dis Clin North Am. 2000 Dec;14(4):1001-16. Review.

PMID:
11144638
6.

HIV Vaccine efficacy trial: glimmers of hope and the potential role of antibody-dependent cellular cytotoxicity.

Wren L, Kent SJ.

Hum Vaccin. 2011 Apr;7(4):466-73. Epub 2011 Apr 1. Review.

PMID:
21389779
7.

[Development of HIV vaccines].

Shibata R.

Nihon Rinsho. 2002 Apr;60(4):790-7. Review. Japanese.

PMID:
11968790
8.

Clinical trials of HIV vaccines.

Graham BS.

Annu Rev Med. 2002;53:207-21. Review.

PMID:
11818471
9.

Immunology of HIV infection and AIDS: memorandum from a WHO/IUIS meeting.

[No authors listed]

Bull World Health Organ. 1987;65(4):453-63. Review.

10.

Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate.

Bellino S, Francavilla V, Longo O, Tripiciano A, Paniccia G, Arancio A, Fiorelli V, Scoglio A, Collacchi B, Campagna M, Lazzarin A, Tambussi G, Din CT, Visintini R, Narciso P, Antinori A, D'Offizi G, Giulianelli M, Carta M, Di Carlo A, Palamara G, Giuliani M, Laguardia ME, Monini P, Magnani M, Ensoli F, Ensoli B.

Rev Recent Clin Trials. 2009 Sep;4(3):195-204. Review.

PMID:
20028332
11.

Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV.

Vaccari M, Poonam P, Franchini G.

Expert Rev Vaccines. 2010 Sep;9(9):997-1005. doi: 10.1586/erv.10.104. Review.

PMID:
20822342
12.

Adjuvants.

Edelman R, Tacket CO.

Int Rev Immunol. 1990;7(1):51-66. Review.

PMID:
2132879
13.

Induction of immunity to human immunodeficiency virus type-1 by vaccination.

McElrath MJ, Haynes BF.

Immunity. 2010 Oct 29;33(4):542-54. doi: 10.1016/j.immuni.2010.09.011. Review.

14.

HIV vaccine could use a little help.

Wang J, Jin X.

Hum Vaccin. 2010 Jun;6(6):476-81. Epub 2010 Jun 1. Review.

PMID:
20671440
15.

NIH conference. HIV vaccine development: a progress report.

Hoth DF, Bolognesi DP, Corey L, Vermund SH.

Ann Intern Med. 1994 Oct 15;121(8):603-11. Review.

PMID:
8085693
16.

Limitations to the structure-based design of HIV-1 vaccine immunogens.

Van Regenmortel MH.

J Mol Recognit. 2011 Sep-Oct;24(5):741-53. doi: 10.1002/jmr.1116. Review.

PMID:
21812050
17.

HIV-1 vaccines: challenges and new perspectives.

Excler JL, Robb ML, Kim JH.

Hum Vaccin Immunother. 2014;10(6):1734-46. doi: 10.4161/hv.28462. Epub 2014 Mar 17. Review.

18.

Immunologic adjuvants for modern vaccine formulations.

Vogel FR.

Ann N Y Acad Sci. 1995 May 31;754:153-60. Review.

PMID:
7625649
19.

[Development of vaccines for HIV-1. Relevance of subtype-specific cellular immunity].

Rodríguez AM, Turk G, Pascutti MF, Falivene J, Gherardi MM.

Medicina (B Aires). 2010;70(6):543-54. Review. Spanish.

PMID:
21163746
20.

Update on progress in HIV vaccine development.

Watkins DI.

Top Antivir Med. 2012 Jun-Jul;20(2):30-1. Review.

Supplemental Content

Support Center